• Home
  • Contact Us
  • Try it!
  • Graphs
  • Publications
  • Blog

Follow us

Recent Posts

  • NEWROAD final meeting April 28, 2026
  • Biovista Vizit New Corpus: ClinicalTrials.gov September 16, 2025
  • Biovista Vizit New Corpus: MATISSE (a SoftMining algorithm) May 13, 2025
  • Biovista Vizit New Corpus: HPO March 4, 2025
  • Biovista Vizit January 2025 Release – AOP Features January 30, 2025

Biovista Vizit

Biovista Vizit

  • Try it!
  • Graphs
  • Publications
  • Blog

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndromeEftychia Lekka2020-08-03T14:03:26-04:00
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19.

Explore the live graph.

Tags: ACE, ACUTE RESPIRATORY DISTRESS SYNDROME, ALTERNATIVE, C5, COMPLEMENT ACTIVATION, COMPLEMENT C3, COMPLEMENT PATHWAY, COVID-19, ECULIZUMAB, GLOMERULAR FILTRATION RATE, GRAFT SURVIVAL, HEMOGLOBIN, HEMOLYSIS, IL6, IMMUNITY, PLATELET COUNT, SARS-COV-2

Post navigation

← Pathways and cell types related to Amantadine’s MoA in COVID-19
Mechanistic analysis of combination IFB-a2b chlorpheniramine, ibuprofen →
TAUOPATHIES TGF-BETA TUMOR PROGRESSION TIMELESS ULCERATIVE COLITIS TMPRSS2 VIRUS DISEASES TRANSPORT TRANSLATION WOUND HEALING VEGF TRASTUZUMAB VASODILATION TRACHEA VITAMIN D THROMBOSIS TYPE 2 DIABETES UCHL1 PROTEIN Uberon THORAX TROPISM TAU UBIQUITINATION THY-1 ANTIGENS THROMBOCYTOPENIA THROMBIN TISSUE DEVELOPMENT TUMOR X-RAY COMPUTED TOMOGRAPHY TARGET LESION IDENTIFICATION VEINS VASCULAR TROGLITAZONE TUMOR GROWTH VASOCONSTRICTION TH17 CELLS TREPONEMA DENTICOLA TP53 VEGFA VERO CELLS VIRAL RELEASE FROM HOST CELL VGF PROTEIN TECFIDERA

© 2026 Biovista Vizit All Rights Reserved.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}